Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

Pfizer clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3276
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Pfizer
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Pfizer. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 229–240 of 3,276 matching trials for sponsor Pfizer.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

NCT05217446
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Encorafenib, Cetuximab, Pembrolizumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Miami Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Active, not recruiting Phase 2 Interventional

Axitinib + Ipilimumab in Advanced Melanoma

NCT04996823
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Axitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Completed Phase 2 Interventional Results available

CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

NCT01134575
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
CMC-544 (Inotuzumab Ozogamycin), Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Completed No phase listed Observational

African Cancer Genome: GMD

NCT05754658
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Standard of Care
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Recruiting Phase 2 Interventional

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

NCT05765500
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Relugolix, Leuprolide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Recruiting Not applicable Interventional

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

NCT05327465
View directory record Official record
Conditions
Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic
Interventions
Aerobic and resistance exercise, Usual Care
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Recruiting Phase 2 Interventional

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

NCT05357794
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
Brentuximab vedotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

NCT02912572
View directory record Official record
Conditions
Metastatic Endometrial Cancer
Interventions
Avelumab, Talazoparib, Axitinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults

NCT07731100
View directory record Official record
Conditions
Healthy Adults
Interventions
Prifetrastat
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Active, not recruiting Phase 2 Interventional

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

NCT02942355
View directory record Official record
Conditions
Female Breast Carcinoma, Breast Cancer
Interventions
anastrozole, Palbociclib
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.

NCT07575906
View directory record Official record
Conditions
Healthy
Interventions
PF-08057418, Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.)
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 27, 2026, 6:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

NCT03374332
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gemtuzumab Ozogamicin (GO), Donor Leukocytes
Drug · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 27, 2026, 6:49 PM EDT

About this Pfizer sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Pfizer is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pfizer trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Pfizer.